Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Feb
18
Today In Oncology
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
Pleurectomy Decortication Safe in Select Patients With Pleural Mesothelioma
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Chemoradiation Plus Atezolizumab in Limited-Stage Small Cell Lung Cancer
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo